Purchase of BioComp Gradient Maker and Fractionator

General Information Document Type: Presolicitation Synopsis Number: 75N98026Q00908 Posted Date: July 29, 2026 Original Response Date: August 10, 2026 Current Response Date: August 10, 2026 Set Aside: N/A NAICS Code: 334516 Contracting Office Address National Institutes of Health (NIH), Office of the Director (OD) Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM) Hospital and Laboratory Support Division 6701 Rockledge Drive Bethesda, MD 20817 Description INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Franklin Young International Inc. 1042 N. Mountain Ave. #310 Upland, CA 91786 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 334516 with a Size Standard N/A. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: Purchase of BioComp Gradient Maker and Fractionator Background Information: A key focus of the UOB has been to translate our understanding of the biology of human genitourinary tumors into clinically viable therapeutic strategies. In recent years, numerous projects in our branch have focused on metabolic changes that occur during prostate cancer progression or result from genetic mutations in kidney cancer. Our efforts have been limited in recent years by our inability to isolate highquality subcellular samples which rely on sucrose gradient ultracentrifuge techniques. Purchase of the BioComp gradient maker and fractionator allow for the reproducible generation of continuous sucrose gradients and fractionation of relevant samples. This purchase is compatible with existing equipment of our neighboring branch (Pediatric Oncology Branch) and will be available for their use as well. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by July 29, 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98026Q00908. Responses may be submitted electronically to Mr. James Law, Contracting Officer at James.Law@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.